Results 41 to 50 of about 18,118,892 (286)

Quality adjusted life years in the time of COVID-19 [PDF]

Australian Health Review, 2021
The quality adjusted life year (QALY) as a basis of valuing additional expenditure on health is widely accepted. Although early in the COVID-19 pandemic, several commentators called for a similar approach in resolving trade-offs between economic activity and reducing the burden of COVID-19, this has not occurred.
Hall, Jane, Viney, Rosalie
openaire   +2 more sources

Eliciting a value set for the Swedish capability-adjusted life years instrument (CALY-SWE) [PDF]

, 2023
Purpose: Our aim was to elicit a value set for Capability-Adjusted Life Years Sweden (CALY-SWE); a capability-grounded quality of life instrument intended for use in economic evaluations of social interventions with broad consequences beyond health ...
Norström, Fredrik, Lindholm, Lars, Ssegonja, R, Ssegonja, Richard, Månsdotter, A, Norström, F, Feldman, Inna,, Mulhern, B, Hjelte, Jan, Lindholm, L, Norström, Fredrik,, Meili, Kaspar Walter, Ssegonja, Richard,, Meili, KW, Hjelte, J, Lindholm, Lars,, Månsdotter, Anna, Mulhern, Brendan,, Månsdotter, Anna,, Mulhern, Brendan, Hjelte, Jan,, Feldman, Inna, Meili, Kaspar Walter,, Feldman, I   +23 more
core   +1 more source

A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan

Journal of the Formosan Medical Association, 2013
The newly available iron chelator deferasirox (Exjade, Novartis) is expected to provide better long-term clinical outcomes and improved quality of life for patients with thalassemia than its predecessor, deferoxamine (Desferal, Novartis), because of its ...
Wan-Ling Ho, Kuo-Piao Chung, Szu-Sheng Yang, Meng-Yao Lu, Shiann-Tarng Jou, Hsiu-Hao Chang, Yung-Li Yang, Dong-Tsamn Lin, Kai-Hsin Lin   +8 more
doaj   +1 more source

An exploratory study to estimate cost-effectiveness threshold value for life saving treatments in western Iran

Cost Effectiveness and Resource Allocation, 2020
Background Cost-effectiveness analysis provides a crucial means for evidence-informed decision-making on resource allocation. This study aims to elicit individuals' willingness to pay (WTP) for one additional quality-adjusted life-year (QALY) gained from
Najmeh Moradi, Abraha Woldemichael, Parisa Malekian, Delnia Moradi Rotvandi, Satar Rezaei   +4 more
doaj   +1 more source

Life year (LY) and quality-adjusted life year (QALY) gained by age for fibrosis stages F1-F4 (Fig 1A-1D).

, 2016
Life year (LY) and quality-adjusted life year (QALY) gained by age for fibrosis stages F1-F4 (Fig 1A-1D).
Ehud Melzer (3154719), Yaakov Maor (3154713), Stephen D. H. Malnick (3154722), Moshe Leshno (3154716)   +3 more
core   +1 more source

Base-case results of expected mortality, cost, and quality-adjusted life-year (QALY) loss.

, 2018
Base-case results of expected mortality, cost, and quality-adjusted life-year (QALY) loss.
Nok-hang Leung (5563508), Joyce H. S. You (318736), Margaret Ip (225393), Minghuan Jiang (440640)   +3 more
core   +1 more source

Costs and quality of life in a randomized trial comparing minimally invasive and open distal pancreatectomy (LEOPARD trial) [PDF]

, 2019
Background: Minimally invasive distal pancreatectomy decreases time to functional recovery compared with open distal pancreatectomy, but the cost-effectiveness and impact on disease-specific quality of life have yet to be established.
van Santvoort, H. C., Daams, F., Suker, M., de Rooij, T., Besselink, M. G., Dejong, C. H., van Duyn, E. B., Klaase, J. M., de Kleine, R. H., Patijn, G. A., Kazemier, G., Koerkamp, B. Groot, Festen, S., Luyer, M., van Laarhoven, C. J., van Eijck, C. H., van Dam, R. M., van den Boezem, P. B., Gerhards, M. F., Hilal, M. Abu, Boerma, D., Strating, E. A., de Hingh, I. H., van Hilst, J., de Boer, M. T., Steenvoorde, P., Dijkgraaf, M. G., Abu Hilal, M., Groot Koerkamp, B.   +28 more
core   +2 more sources

THE USE OF QALY AS AN INTEGRAL MEASURE OF EFFECTIVENESS IN THE EVALUATION OF MEDICAL TECHNOLOGIES

Фармакоэкономика, 2017
This report addresses the ways of calculating QALY (Quality-adjusted life-year). OutsideRussia, a standardized methodology to calculate QALY is in use; such an approach makes it possible to apply this universal criterion of effectiveness to the ...
N. Z. Musina, V. K. Fedyaeva
doaj   +1 more source

Social Functioning Within the First Years After Pediatric Brain Tumor Diagnosis and the Relationship With Family Psychosocial Risk

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Survivors of pediatric brain tumors (PBTs) can experience long‐term social difficulties, impacting quality of life. Beyond medical and environmental factors, family psychosocial risk may play a role in social outcomes by shaping the caregiving environment and may provide intervention options.
Renske H. Houben, Marisa H. Huisman, Martha A. Grootenhuis, Femke K. Aarsen, Marita Partanen   +4 more
wiley   +1 more source

Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin, Sheila K. Pierson, Kelley C. Dacus, Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Larissa Borys, Kayla McHugh, Abiola Irvine, Yoojin Jo, Adam Bagg, Mary Jo Lechowicz, Daisy Alapat, Amy Chadburn, Megan S. Lim, Gordan Srkalovic, Frits van Rhee, David C. Fajgenbaum, Joshua D. Brandstadter   +17 more
wiley   +1 more source